Back to Journals » Drug Design, Development and Therapy » Volume 12

Identification of novel drug targets in bovine respiratory disease: an essential step in applying biotechnologic techniques to develop more effective therapeutic treatments

Authors Sakharkar MK, Rajamanickam K, Chandra R, Khan HA, Alhomida AS, Yang J

Received 23 January 2018

Accepted for publication 14 March 2018

Published 7 May 2018 Volume 2018:12 Pages 1135—1146

DOI https://doi.org/10.2147/DDDT.S163476

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Dr Tuo Deng


Meena Kishore Sakharkar,1 Karthic Rajamanickam,1 Ramesh Chandra,2 Haseeb A Khan,3 Abdullah S Alhomida,3 Jian Yang1

1College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, Canada; 2Department of Chemistry, University of Delhi, Delhi, India; 3Department of Biochemistry, College of Science, King Saud University, Riyadh, Saudi Arabia

Background: Bovine Respiratory Disease (BRD) is a major problem in cattle production which causes substantial economic loss. BRD has multifactorial aetiologies, is multi-microbial, and several of the causative pathogens are unknown. Consequently, primary management practices such as metaphylactic antimicrobial injections for BRD prevention are used to reduce the incidence of BRD in feedlot cattle. However, this poses a serious threat in the form of development of antimicrobial resistance and demands an urgent need to find novel interventions that could reduce the effects of BRD drastically and also delay/prevent bacterial resistance.
Materials and methods: We have employed a subtractive genomics approach that helps delineate essential, host-specific, and druggable targets in pathogens responsible for BRD. We also proposed antimicrobials from FDA green and orange book that could be repositioned for BRD.
Results: We have identified 107 putative targets that are essential, selective and druggable. We have also confirmed the susceptibility of two BRD pathogens to one of the proposed antimicrobials – oxytetracycline.
Conclusion: This approach allows for repositioning drugs known for other infections to BRD, predicting novel druggable targets for BRD infection, and providing a new direction in developing more effective therapeutic treatments for BRD.

Keywords: BRD, pathogenic bacteria, targets, drugs, prioritization, differential genome analyses, druggability

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]